Mogrify wins Business Weekly award for ‘Disruptive Technology’

Direct cellular conversion technology recognized at prestigious business awards.

Mogrify’s proprietary direct cellular conversion technology takes a systematic big-data approach (Rackham et al., Nature Genetics, 2016) to identify the factors needed to drive the conversion of one mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.

Mogrify’s approach is faster and more accessible than iPSC-based protocols as it doesn’t require a licence to use Yamanaka factors to induce pluripotency, it eliminates the need for a two-step approach involving reprograming and differentiation to allow for one-step transdifferentiation, and it produces mature cells rather than converting stems cells to progenitor cells via methods that mimic natural development, which can be slow and time-consuming.

The Company is applying its patented technology to generate IP and accelerate the development and manufacture of regenerative cell therapies across every therapeutic area.

Professor Julian Gough, Co-founder and CSO, Mogrify, said: “This award is testament to the dedication of Mogrify’s multidisciplinary team who have invested their time and expertise in bioinformatics, cell reprograming and machine learning to deliver a direct cellular conversion platform, powered by next-generation sequencing and gene-regulatory data. Mogrify’s mission is to transform the future of cell therapy and it is an honor to have our disruptive technology recognized at the Business Weekly Awards.”